The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin production in these patients, based on positive results from the PROTECT phase 3 study involving over 900 patients. Tzield targets the autoimmune attack on insulin-producing beta cells, potentially changing the treatment approach for stage 3 T1D. Continued approval depends on further confirmatory studies, with ongoing trials like BETA-PRESERVE underway.
Novavax reported $68 million in revenue for Q3 2026, slightly down from last year, but raised its full-year 2026 revenue forecast to $400 million at the midpoint. The company earned a $125 million milestone from Sanofi's launch of a Phase 3 influenza...
Sanofi has decided to discontinue the Phase 1 clinical trial and development of SAR448272, an oral STAT6 degrader developed in collaboration with Nurix Therapeutics. As a result, Nurix will no longer receive milestone payments or royalties related to...
